{"id":{"repo_id":"uiuc","oai_identifier":"oai:www.ideals.illinois.edu:2142/101367"},"canonical_url":"https://search.dev.ndltd.org/etd/uiuc/oai:www.ideals.illinois.edu:2142/101367","repository":{"repo_id":"uiuc","name":"University of Illinois - Urbana-Champaign","base_url":"https://www.ideals.illinois.edu/oai-pmh"},"display":{"title":"Combinatorial therapy for triple negative breast cancer and the effect of nanoscale surfaces","abstract":"Triple negative breast cancer (TNBC) is a highly aggressive type of breast cancer with urgent clinical need for effective therapies. Resistance to standard clinical therapies with metastatic TNBC pushed the researchers to explore combinatorial therapy regime. A combination of STAT-3 specific inhibitor, reported to act synergistically with metformin in reducing cell growth and inducing apoptosis in TNBCs and agents targeting DNA repair, can produce a new approach to TNBC therapy. Towards this aim, we have generated a combinatorial drug formulation comprising DNA damage repair agents, along with inhibitors for STAT-3 for an optimized effect. The combinatorial formulation includes nifuroxazide, a known STAT-3 inhibitor, and amonafide, an agent known to exert its effect through topoisomerase-II activation pathways. An additional incorporation of pentoxifylline, a methylxanthine derivative known for anti-metastatic effects in breast cancers, could further improve the efficiency. We used drug combination of nifuroxazide, amonafide and pentoxifylline in MDA-MB-231, HCC1806, HCC1143 and BT-549 TNBCs along with normal breast cells, MCF-7 and SkBr3, to find the combinatorial index of the drug cocktail. It was found that combination of pentoxifylline, nifuroxazide and amonafide resulted in a combinatorial index of 0.82 in HCC1806 cells. We also investigated the gene and protein expression effects exerted by combination of drugs responsible to induce synergistic effect and simultaneously suppressing drug resistance through distinct mechanisms of action. Next, we demonstrate that phenotypically stratified carbon nanoparticle is highly effective in delivering a novel combinatorial triple drug formulation for synergistic regression of TNBC in vitro and in vivo. The combinatorial formulation is comprised of repurposed inhibitors of STAT3 (nifuroxazide), topoisomerase-II-activation-pathway (amonafide) and NFb (pentoxifylline). Synergistic effect of drug combination was established in a panel of TNBC-lines comprising mesenchymal-stem-like, mesenchymal and basal-like cells along with non-TNBC-cells. The delivery of combinatorial drug formulation was achieved using a phenotypically screened carbon nanoparticles for TNBC cell lines. Results indicated a remarkable five-fold improvement (IC50-6.75μM) from the parent drugs with a combinatorial index < 1 in majority of the TNBC cells. Multi-compartmental carbon nanoparticles were then parametrically assessed based on size, charge (positive/negative/neutral) and chemistry (functionalities) to study their likelihood of crossing endocytic barriers from phenotypical standpoint in TNBC lines. Interestingly, a combination of clathrin mediated, energy and dynamin dependent pathways were predominant for sulfonated nanoparticles, whereas pristine and phospholipid particles followed all the investigated endocytic pathways. An exactitude ‘omics’ approach helps to predict that phospholipid encapsulated-particles will predominantly accumulate in TNBC comprising the drug ‘cocktail’. Thus, our efforts might generate a novel triple drug combination as an answer to current TNBC related shortcomings.","abstract_html":"Triple negative breast cancer (TNBC) is a highly aggressive type of breast cancer with urgent clinical need for effective therapies. Resistance to standard clinical therapies with metastatic TNBC pushed the researchers to explore combinatorial therapy regime. A combination of STAT-3 specific inhibitor, reported to act synergistically with metformin in reducing cell growth and inducing apoptosis in TNBCs and agents targeting DNA repair, can produce a new approach to TNBC therapy. Towards this aim, we have generated a combinatorial drug formulation comprising DNA damage repair agents, along with inhibitors for STAT-3 for an optimized effect. The combinatorial formulation includes nifuroxazide, a known STAT-3 inhibitor, and amonafide, an agent known to exert its effect through topoisomerase-II activation pathways. An additional incorporation of pentoxifylline, a methylxanthine derivative known for anti-metastatic effects in breast cancers, could further improve the efficiency. We used drug combination of nifuroxazide, amonafide and pentoxifylline in MDA-MB-231, HCC1806, HCC1143 and BT-549 TNBCs along with normal breast cells, MCF-7 and SkBr3, to find the combinatorial index of the drug cocktail. It was found that combination of pentoxifylline, nifuroxazide and amonafide resulted in a combinatorial index of 0.82 in HCC1806 cells. We also investigated the gene and protein expression effects exerted by combination of drugs responsible to induce synergistic effect and simultaneously suppressing drug resistance through distinct mechanisms of action. Next, we demonstrate that phenotypically stratified carbon nanoparticle is highly effective in delivering a novel combinatorial triple drug formulation for synergistic regression of TNBC in vitro and in vivo. The combinatorial formulation is comprised of repurposed inhibitors of STAT3 (nifuroxazide), topoisomerase-II-activation-pathway (amonafide) and NFb (pentoxifylline). Synergistic effect of drug combination was established in a panel of TNBC-lines comprising mesenchymal-stem-like, mesenchymal and basal-like cells along with non-TNBC-cells. The delivery of combinatorial drug formulation was achieved using a phenotypically screened carbon nanoparticles for TNBC cell lines. Results indicated a remarkable five-fold improvement (IC50-6.75μM) from the parent drugs with a combinatorial index &lt; 1 in majority of the TNBC cells. Multi-compartmental carbon nanoparticles were then parametrically assessed based on size, charge (positive/negative/neutral) and chemistry (functionalities) to study their likelihood of crossing endocytic barriers from phenotypical standpoint in TNBC lines. Interestingly, a combination of clathrin mediated, energy and dynamin dependent pathways were predominant for sulfonated nanoparticles, whereas pristine and phospholipid particles followed all the investigated endocytic pathways. An exactitude ‘omics’ approach helps to predict that phospholipid encapsulated-particles will predominantly accumulate in TNBC comprising the drug ‘cocktail’. Thus, our efforts might generate a novel triple drug combination as an answer to current TNBC related shortcomings.","abstract_has_math":false,"creators":["Kampert, Taylor"],"institution":"University of Illinois at Urbana-Champaign","degree_name":"M.S.","degree_level":"Thesis","degree_discipline":"Bioengineering","degree_department":null,"school":null,"contributors":["Pan, Dipanjan"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2018,"date_issued":"2018-09-04T20:47:29Z","date_published":"2018-09-04T20:47:29Z","updated_at":"2026-07-22T22:24:40Z","subjects":["Combinatorial","nanosurface","triple negative breast cancer","carbon nanoparticles","therapy"],"languages":["en"],"rights":["Copyright 2018 Taylor Kampert"],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/2142/101367","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Pan, Dipanjan"]},{"key":"dc:creator","label":"Author","values":["Kampert, Taylor"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2018-09-04T20:47:29Z","2020-09-05T09:15:32Z","2018-04-25","2018-05"]},{"key":"dc:type","label":"Dc Type","values":["text"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Bioengineering"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["M.S."]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of Illinois at Urbana-Champaign"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Combinatorial","nanosurface","triple negative breast cancer","carbon nanoparticles","therapy"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["Copyright 2018 Taylor Kampert"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://hdl.handle.net/2142/101367"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Triple negative breast cancer (TNBC) is a highly aggressive type of breast cancer with urgent clinical need for effective therapies. Resistance to standard clinical therapies with metastatic TNBC pushed the researchers to explore combinatorial therapy regime. A combination of STAT-3 specific inhibitor, reported to act synergistically with metformin in reducing cell growth and inducing apoptosis in TNBCs and agents targeting DNA repair, can produce a new approach to TNBC therapy. Towards this aim, we have generated a combinatorial drug formulation comprising DNA damage repair agents, along with inhibitors for STAT-3 for an optimized effect. The combinatorial formulation includes nifuroxazide, a known STAT-3 inhibitor, and amonafide, an agent known to exert its effect through topoisomerase-II activation pathways. An additional incorporation of pentoxifylline, a methylxanthine derivative known for anti-metastatic effects in breast cancers, could further improve the efficiency. We used drug combination of nifuroxazide, amonafide and pentoxifylline in MDA-MB-231, HCC1806, HCC1143 and BT-549 TNBCs along with normal breast cells, MCF-7 and SkBr3, to find the combinatorial index of the drug cocktail. It was found that combination of pentoxifylline, nifuroxazide and amonafide resulted in a combinatorial index of 0.82 in HCC1806 cells. We also investigated the gene and protein expression effects exerted by combination of drugs responsible to induce synergistic effect and simultaneously suppressing drug resistance through distinct mechanisms of action. Next, we demonstrate that phenotypically stratified carbon nanoparticle is highly effective in delivering a novel combinatorial triple drug formulation for synergistic regression of TNBC in vitro and in vivo. The combinatorial formulation is comprised of repurposed inhibitors of STAT3 (nifuroxazide), topoisomerase-II-activation-pathway (amonafide) and NFb (pentoxifylline). Synergistic effect of drug combination was established in a panel of TNBC-lines comprising mesenchymal-stem-like, mesenchymal and basal-like cells along with non-TNBC-cells. The delivery of combinatorial drug formulation was achieved using a phenotypically screened carbon nanoparticles for TNBC cell lines. Results indicated a remarkable five-fold improvement (IC50-6.75μM) from the parent drugs with a combinatorial index < 1 in majority of the TNBC cells. Multi-compartmental carbon nanoparticles were then parametrically assessed based on size, charge (positive/negative/neutral) and chemistry (functionalities) to study their likelihood of crossing endocytic barriers from phenotypical standpoint in TNBC lines. Interestingly, a combination of clathrin mediated, energy and dynamin dependent pathways were predominant for sulfonated nanoparticles, whereas pristine and phospholipid particles followed all the investigated endocytic pathways. An exactitude ‘omics’ approach helps to predict that phospholipid encapsulated-particles will predominantly accumulate in TNBC comprising the drug ‘cocktail’. Thus, our efforts might generate a novel triple drug combination as an answer to current TNBC related shortcomings.","Submission published under a 24 month embargo labeled 'Closed Access', the embargo will last until 2020-05-01","The student, Taylor Kampert, accepted the attached license on 2018-04-25 at 10:13.","The student, Taylor Kampert, submitted this Thesis for approval on 2018-04-25 at 10:21.","This Thesis was approved for publication on 2018-04-25 at 13:52.","DSpace SAF Submission Ingestion Package generated from Vireo submission #12422 on 2018-08-31 at 17:30:16","Made available in DSpace on 2018-09-04T20:47:29Z (GMT). No. of bitstreams: 3 KAMPERT-THESIS-2018.pdf: 7339393 bytes, checksum: b4ba06c4c576438d84e5d07d657a109b (MD5) MS_Thesis_TK.docx: 9535837 bytes, checksum: 35eca19d47b7c39d83d2843721c8e308 (MD5) LICENSE.txt: 4211 bytes, checksum: 14676fcd07e551c16d91f6d578e87707 (MD5) Previous issue date: 2018-04-25","Embargo set by: Seth Robbins for item 107452 Lift date: 2020-09-04T20:47:38Z Reason: Author requested closed access (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 107452 Lift date: 2020-09-04T20:50:11Z Reason: Author requested closed access (OA after 2yrs) in Vireo ETD system","Limited Restriction Lifted for Item 107452 on 2020-09-05T09:15:32Z."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["Combinatorial therapy for triple negative breast cancer and the effect of nanoscale surfaces"]}]}],"canonical_facts":{"dc:contributor":["Pan, Dipanjan"],"dc:creator":["Kampert, Taylor"],"dc:date":["2018-09-04T20:47:29Z","2020-09-05T09:15:32Z","2018-04-25","2018-05"],"dc:description":["Triple negative breast cancer (TNBC) is a highly aggressive type of breast cancer with urgent clinical need for effective therapies. Resistance to standard clinical therapies with metastatic TNBC pushed the researchers to explore combinatorial therapy regime. A combination of STAT-3 specific inhibitor, reported to act synergistically with metformin in reducing cell growth and inducing apoptosis in TNBCs and agents targeting DNA repair, can produce a new approach to TNBC therapy. Towards this aim, we have generated a combinatorial drug formulation comprising DNA damage repair agents, along with inhibitors for STAT-3 for an optimized effect. The combinatorial formulation includes nifuroxazide, a known STAT-3 inhibitor, and amonafide, an agent known to exert its effect through topoisomerase-II activation pathways. An additional incorporation of pentoxifylline, a methylxanthine derivative known for anti-metastatic effects in breast cancers, could further improve the efficiency. We used drug combination of nifuroxazide, amonafide and pentoxifylline in MDA-MB-231, HCC1806, HCC1143 and BT-549 TNBCs along with normal breast cells, MCF-7 and SkBr3, to find the combinatorial index of the drug cocktail. It was found that combination of pentoxifylline, nifuroxazide and amonafide resulted in a combinatorial index of 0.82 in HCC1806 cells. We also investigated the gene and protein expression effects exerted by combination of drugs responsible to induce synergistic effect and simultaneously suppressing drug resistance through distinct mechanisms of action. Next, we demonstrate that phenotypically stratified carbon nanoparticle is highly effective in delivering a novel combinatorial triple drug formulation for synergistic regression of TNBC in vitro and in vivo. The combinatorial formulation is comprised of repurposed inhibitors of STAT3 (nifuroxazide), topoisomerase-II-activation-pathway (amonafide) and NFb (pentoxifylline). Synergistic effect of drug combination was established in a panel of TNBC-lines comprising mesenchymal-stem-like, mesenchymal and basal-like cells along with non-TNBC-cells. The delivery of combinatorial drug formulation was achieved using a phenotypically screened carbon nanoparticles for TNBC cell lines. Results indicated a remarkable five-fold improvement (IC50-6.75μM) from the parent drugs with a combinatorial index < 1 in majority of the TNBC cells. Multi-compartmental carbon nanoparticles were then parametrically assessed based on size, charge (positive/negative/neutral) and chemistry (functionalities) to study their likelihood of crossing endocytic barriers from phenotypical standpoint in TNBC lines. Interestingly, a combination of clathrin mediated, energy and dynamin dependent pathways were predominant for sulfonated nanoparticles, whereas pristine and phospholipid particles followed all the investigated endocytic pathways. An exactitude ‘omics’ approach helps to predict that phospholipid encapsulated-particles will predominantly accumulate in TNBC comprising the drug ‘cocktail’. Thus, our efforts might generate a novel triple drug combination as an answer to current TNBC related shortcomings.","Submission published under a 24 month embargo labeled 'Closed Access', the embargo will last until 2020-05-01","The student, Taylor Kampert, accepted the attached license on 2018-04-25 at 10:13.","The student, Taylor Kampert, submitted this Thesis for approval on 2018-04-25 at 10:21.","This Thesis was approved for publication on 2018-04-25 at 13:52.","DSpace SAF Submission Ingestion Package generated from Vireo submission #12422 on 2018-08-31 at 17:30:16","Made available in DSpace on 2018-09-04T20:47:29Z (GMT). No. of bitstreams: 3 KAMPERT-THESIS-2018.pdf: 7339393 bytes, checksum: b4ba06c4c576438d84e5d07d657a109b (MD5) MS_Thesis_TK.docx: 9535837 bytes, checksum: 35eca19d47b7c39d83d2843721c8e308 (MD5) LICENSE.txt: 4211 bytes, checksum: 14676fcd07e551c16d91f6d578e87707 (MD5) Previous issue date: 2018-04-25","Embargo set by: Seth Robbins for item 107452 Lift date: 2020-09-04T20:47:38Z Reason: Author requested closed access (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 107452 Lift date: 2020-09-04T20:50:11Z Reason: Author requested closed access (OA after 2yrs) in Vireo ETD system","Limited Restriction Lifted for Item 107452 on 2020-09-05T09:15:32Z."],"dc:format":["application/pdf"],"dc:identifier":["http://hdl.handle.net/2142/101367"],"dc:language":["en"],"dc:rights":["Copyright 2018 Taylor Kampert"],"dc:subject":["Combinatorial","nanosurface","triple negative breast cancer","carbon nanoparticles","therapy"],"dc:title":["Combinatorial therapy for triple negative breast cancer and the effect of nanoscale surfaces"],"dc:type":["text"],"thesis:degree_discipline":["Bioengineering"],"thesis:degree_level":["Thesis"],"thesis:degree_name":["M.S."],"thesis:institution_name":["University of Illinois at Urbana-Champaign"]},"updated_at":"2026-07-22T22:24:40Z"}